A TIGIT/CD226 dysbalance with high TIGIT and low CD226 expression on intra-tumoral NK cells been shown in multiple human tumors, e.g. colorectal cancer (CRC) (98), ovarian cancer (100) and HCC (101), and compromises intra-tumoral NK cell functions. This evidence concerns the gene CD226 and hepatocellular carcinoma.